5 reasons why it is worth using ezetimibe Review article
Article Sidebar
Main Article Content
Abstract
Elevated cholesterol is one of the main cardiovascular risk factors. Its reduction, on the other hand, improves s-n risk. Therefore, it must be treated effectively. The primary drug in the treatment of dyslipidemia is statins. In many patients, especially those who do not reach target LDL cholesterol levels on statin-only treatment, ezetimibe should be added to the therapy. This is a very good solution, as ezetimibe combined with a potent statin is a very effective hypolipemic. In addition, ezetimibe is also a good option for people who are intolerant of statins or disagree with taking them.
Article Details
How to Cite
Dobrowolski, P. (2023). 5 reasons why it is worth using ezetimibe. Medycyna Faktow (J EBM), 16(4(61), 317-319. https://doi.org/10.24292/01.MF.0423.04
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Murphy SA, Cannon CP, Blazing MA et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: The improve-it trial. J Am Coll Cardiol. 2016; 67: 353-61.
2. Pandor A, Ara RM, Tumur I et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: Systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009; 265: 568-80.
3. Mach F, Baigent C, Catapano AL et al.; Group ESCSD. 2019 esc/eas guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111-88.
2. Pandor A, Ara RM, Tumur I et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: Systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009; 265: 568-80.
3. Mach F, Baigent C, Catapano AL et al.; Group ESCSD. 2019 esc/eas guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111-88.